CADL
Closed
Candel Therapeutics Inc
4.85
-0.21 (-4.15%)
Last Update: 01 Jul 2025 23:00:00
Yesterday: 5.06
Day's Range: 4.7292 - 4.955
Send
sign up or login to leave a comment!
When Written:
1.35
Candel Therapeutics Inc is a clinical-stage biotechnology company that focuses on developing innovative immunotherapies for cancer treatment. The company's proprietary CANDEL technology platform utilizes oncolytic viruses and immune checkpoint inhibitors to stimulate the immune system's response to cancer cells.
Candel Therapeutics was founded in 2016 and is headquartered in Waltham, Massachusetts. The company has a pipeline of product candidates in various stages of development, including Candel-201, a Phase 1/2 clinical trial for solid tumors and lymphoma, and Candel-101, a preclinical program for glioblastoma.
The company has received funding from various sources, including venture capital firms, government grants, and partnerships with pharmaceutical companies. In 2021, Candel Therapeutics announced a merger with privately held biotech company, private biotech company Anjarium Biosciences, to expand its pipeline of cancer immunotherapies.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
Candel Therapeutics was founded in 2016 and is headquartered in Waltham, Massachusetts. The company has a pipeline of product candidates in various stages of development, including Candel-201, a Phase 1/2 clinical trial for solid tumors and lymphoma, and Candel-101, a preclinical program for glioblastoma.
The company has received funding from various sources, including venture capital firms, government grants, and partnerships with pharmaceutical companies. In 2021, Candel Therapeutics announced a merger with privately held biotech company, private biotech company Anjarium Biosciences, to expand its pipeline of cancer immunotherapies.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
(0)
(0)
Send
sign up or login to leave a comment!!








